S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NYSE:RDY

Dr. Reddy's Laboratories (RDY) Stock Forecast, Price & News

$66.88
+0.84 (+1.27%)
(As of 09/29/2023 ET)
Compare
Today's Range
$66.85
▼
$67.83
50-Day Range
$65.49
▼
$72.76
52-Week Range
$50.46
▼
$73.17
Volume
255,159 shs
Average Volume
240,658 shs
Market Capitalization
$11.16 billion
P/E Ratio
19.33
Dividend Yield
0.61%
Price Target
$70.00
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Dr. Reddy's Laboratories MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
4.7% Upside
$70.00 Price Target
Short Interest
Bearish
1.04% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.52mentions of Dr. Reddy
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.97%
From $3.79 to $4.13 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

893rd out of 973 stocks

Pharmaceutical Preparations Industry

419th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

RDY stock logo

About Dr. Reddy's Laboratories (NYSE:RDY) Stock

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

RDY Price History

RDY Stock News Headlines

September 29, 2023 | finance.yahoo.com
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals
September 26, 2023 | finance.yahoo.com
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
September 29, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
September 26, 2023 | americanbankingnews.com
Dr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average of $61.95
September 25, 2023 | finance.yahoo.com
Why Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
September 18, 2023 | finance.yahoo.com
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now
September 13, 2023 | finance.yahoo.com
Zacks.com featured highlights Caterpillar, KB Home, Walmart, Dr. Reddy's Laboratories and FedEx
September 8, 2023 | msn.com
These 3 Low-Beta Stocks Sport High Growth
September 29, 2023 | Tradewins (Ad)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
August 31, 2023 | finance.yahoo.com
Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice
August 18, 2023 | msn.com
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
August 14, 2023 | finance.yahoo.com
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
August 10, 2023 | msn.com
Dr. Reddy's launches generic version of Kombiglyze XR in US
August 10, 2023 | seekingalpha.com
Dr. Reddy's Laboratories Limited 2024 Q1 - Results - Earnings Call Presentation
July 28, 2023 | msn.com
Chart of the Day: What's Cooking at Dr. Reddy's Lab
July 28, 2023 | finance.yahoo.com
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
July 27, 2023 | finance.yahoo.com
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q1 2024 Earnings Call Transcript
July 27, 2023 | chron.com
Doctor Reddy's: Fiscal Q1 Earnings Snapshot
July 27, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY), LivaNova (LIVN) and Thermo Fisher (TMO)
July 27, 2023 | markets.businessinsider.com
Dr Reddys Laboratories earnings preview: what Wall Street is expecting
July 27, 2023 | reuters.com
India's Dr.Reddy's posts 18% rise in Q1 profit on strong generic drugs sales
July 12, 2023 | finance.yahoo.com
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
June 14, 2023 | marketwatch.com
Dr. Reddy's Laboratories falls Wednesday, underperforms market
June 7, 2023 | seekingalpha.com
Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
June 6, 2023 | finance.yahoo.com
Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study
May 24, 2023 | finance.yahoo.com
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
May 10, 2023 | finance.yahoo.com
Dr. Reddy’s Q4 & FY23 Financial Results
See More Headlines
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Company Calendar

Last Earnings
7/26/2023
Ex-Dividend for 7/28 Dividend
7/28/2023
Dividend Payable
7/28/2023
Today
9/29/2023
Next Earnings (Estimated)
10/27/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:RDY
CUSIP
N/A
CIK
1135951
Web
www.drreddys.com
Phone
914049002900
Fax
91-40-4900-2999
Employees
25,863
Year Founded
1984

Price Target and Rating

Average Stock Price Forecast
$70.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+4.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$3.46
Trailing P/E Ratio
19.39
Forward P/E Ratio
17.70
P/E Growth
1.92
Net Income
$548 million
Net Margins
18.11%
Pretax Margin
24.35%
Return on Equity
20.94%
Return on Assets
15.04%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
2.60
Quick Ratio
1.95

Sales & Book Value

Annual Sales
$2.99 billion
Price / Sales
3.74
Cash Flow
$4.30 per share
Price / Cash Flow
15.60
Book Value
$16.87 per share
Price / Book
3.98

Miscellaneous

Outstanding Shares
166,840,000
Free Float
163,507,000
Market Cap
$11.19 billion
Optionable
Optionable
Beta
0.54

Social Links

Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Gunupati Venkateswara Prasad B.E. (Age 63)
    Co-Chairman, MD & Member of Management Council
    Comp: $2.26M
  • Mr. Kallam Satish Reddy B.Tech. (Age 56)
    M.S., Chairman & Member of the Management Council
    Comp: $1.39M
  • Mr. Erez Israeli M.B.A. (Age 55)
    CEO & Member of the Management Council
  • Mr. Parag Agarwal (Age 56)
    CFO & Member of Management Council
  • Mr. Deepak Sapra M.B.A. (Age 48)
    CEO of API & Services & Member of Management Council
  • Mr. Venkata Ramana Motupalli M.B.A. (Age 54)
    MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council
  • Ms. Archana Bhaskar B.Sc. (Age 56)
    M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council
  • Mr. Sanjay Sharma B.Tech. (Age 55)
    Exec. VP, Global Head of Global Manufacturing & Member of Management Council
  • Mr. Marc Kikuchi B.A. (Age 54)
    M.B.A., CEO of North America Generics & Member of Management Council
  • Mr. Patrick Aghanian B.A. (Age 58)
    M.B.A., CEO of European Generics & Member of Management Council

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













RDY Stock - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.
View RDY analyst ratings or view top-rated stocks.

What is Dr. Reddy's Laboratories' stock price forecast for 2023?

6 Wall Street research analysts have issued 12-month price targets for Dr. Reddy's Laboratories' shares. Their RDY share price forecasts range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for RDY or view top-rated stocks among Wall Street analysts.

How have RDY shares performed in 2023?

Dr. Reddy's Laboratories' stock was trading at $51.75 at the beginning of the year. Since then, RDY stock has increased by 29.6% and is now trading at $67.09.
View the best growth stocks for 2023 here.

When is Dr. Reddy's Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our RDY earnings forecast.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) issued its earnings results on Wednesday, July, 26th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.32. The company had revenue of $820.20 million for the quarter, compared to analyst estimates of $790.67 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.94% and a net margin of 18.11%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Tuesday, July 18th. Stockholders of record on Friday, January 1st will be paid a dividend of $0.4877 per share on Friday, July 28th. This represents a yield of 0.7%. The ex-dividend date is Friday, July 28th. This is a positive change from the stock's previous annual dividend of $0.33.
Read our dividend analysis for RDY.

What ETFs hold Dr. Reddy's Laboratories' stock?

ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include ALPS Emerging Sector Dividend Dogs ETF (EDOG), First Trust BICK Index Fund (BICK), Putnam PanAgora ESG Emerging Markets Equity ETF (PPEM), Inspire Tactical Balanced ETF (RISN), Inspire Fidelis Multi Factor ETF (FDLS), Hartford Multifactor Emerging Markets ETF (ROAM) and Invesco S&P Emerging Markets Low Volatility ETF (EELV).SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG).

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.62%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 11.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.93% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $67.09.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories (NYSE:RDY) has a market capitalization of $11.19 billion and generates $2.99 billion in revenue each year. The company earns $548 million in net income (profit) each year or $3.46 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

The company employs 25,863 workers across the globe.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The official website for the company is www.drreddys.com. The company can be reached via phone at 914049002900, via email at amita@drreddys.com, or via fax at 91-40-4900-2999.

This page (NYSE:RDY) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -